Ask the expert: Are online innovations the future of Parkinson’s treatment?
Author: Sophie BatesPublished: 14 May 2020
Prep: Cook: Serves:
In the latest in our Ask the Expert series, we speak with neurologist Joaquim Ferreira, about the importance of online resources for people with Parkinson’s during the Covid-19 pandemic and how the crisis has led to new forms of clinical communication
Could you tell us how online therapies for people with Parkinson’s are evolving?
Parkinson’s is complex in its clinical presentation – symptoms vary and the condition is not easy to understand, even by healthcare professionals. We are learning that simple aspects regarding the way the diagnosis is made and communicated have prognostic implications, so educating the Parkinson’s community is extremely important.
New healthcare concepts of multidisciplinary and home or community-based interventions are being evaluated in an attempt to define the best way of combining different therapeutic interventions. These new healthcare models include education components and should be addressed in the same way as other health conditions. Likewise, the use of web-based interventions appears as an efficient way to target and hopefully benefit many people with Parkinson’s.
Why is accessing online information about Parkinson’s particularly important during the Covid-19 crisis?
Parkinson’s is a condition that needs continuous follow-up and management, so it’s critical to maintain care and monitoring even when we cannot access clinics in the same way. Keeping up therapeutic programmes is very important to avoid losing the benefits. We have been learning that non-pharmacological treatments – for instance, physiotherapy and speech therapy, have a duration of effect like any drug, so once they are stopped, the effects start to disappear. In the same way that we should not stop taking anti-parkinsonian medication (like drugs that release dopamine or mimic the action of dopamine) without professional advice, therapeutic treatments shouldn’t be stopped.
What role can other online resources play for people with Parkinson’s during the crisis?
The available resources are not enough for the mission we have. Not everything during the pandemic has been negative – this period has forced us to discover new ways that we can be involved in the care of individuals. The use of online tools has allowed us to perform consultations and therapeutic sessions – and we have been able to conclude surprisingly quickly that these tools work.
In terms of the future, online resources will allow a better documentation of what happens in the daily routines of people with Parkinson’s. Physicians will be able to access the real data of individuals from the information collected during face-to-face consultations, which will mean a ‘closer’ follow up – merging outpatient consultations with online interventions and support. So, in my opinion, online visits and sessions are here to stay.
You are the founder of neurological disorders centre Campus Neurológico Sénior (CNS). Could you tell us about the CNS Academy videos and how they benefit people with Parkinson’s?
The main purpose of CNS is to reunite quality clinical activity, leading research projects and training health professionals. The CNS Academy videos present the great work being done by our professionals and highlight our perception that there’s still a huge need for simple and high-quality information for everyone with Parkinson’s. We created these videos because we felt compelled to share the expertise of our dedicated and highly trained professionals – so that others can benefit from their knowledge.
The topics – which were suggested by healthcare professionals working at CNS – try to cover the most frequent and relevant problems that can be addressed by cartoons. They include educational videos on how to manage medication, home safety, how to help the caregiver, speech problems, gait problems etc. The videos’ objective is not just to propose simple tips, but to promote the increase of physical and cognitive training at home, to complement all other interventions applied by professionals in clinics.
How can people ensure that the information they find online about Parkinson’s is accurate and up to date?
It can be extremely difficult to differentiate between high quality data and misinformation. The easiest and most effective way to filter the good from bad is to always favour information published through associations – for instance, the European Parkinson’s Disease Association (EPDA), Parkinson’s Foundation, or organisations with scientific boards validating their content.
It’s important to be cautious when reading news that presents amazing or almost miraculous treatments. We all hope that in the near future we will have huge therapeutic achievements to share – but they will be presented through publications in scientific journals, scientific societies or congresses, and not posted on the web by people who do not have a solid scientific curriculum.
This difficult period reinforces the need for a close and fruitful collaboration between all. It clarifies the need to be humble when dealing with our health and the uncertainties we still have in many fields of knowledge. These strange and unexpected times will end soon, and we should learn from them.
Need to know
Joaquim Ferreira is a neurologist based in Lisbon, Portugal. He has worked in the field of movement disorders and Parkinson’s for the past 25 years and is a professor of neurology and clinical pharmacology at the University of Lisbon. He is also the founder of Campus Neurológico Sénior (CNS) in Portugal, a neurological disorders centre that focuses on multidisciplinary care for people with Parkinson’s.
For more advice on living well with Parkinson’s, please visit the EPDA website.
‘My Dad: his Parkinson’s through my 9-year-old eyes’
We talk to the man who sketches his Parkinson’s symptoms
2 days ago
Does deep brain stimulation for Parkinson’s increase the risk of dementia?
Researchers in France have found that deep brain stimulation for Parkinson’s may not increase the risk of developing dementia. As part of the study – published by the American Academy of Neurology – researchers identified 175 people with Parkinson’s and an average age of 56, who had deep brain stimulation. The individuals were assessed over a period of 10 years to determine if they had developed dementia. After one year, four individuals had developed dementia. After five years, 142 people from the original group were available for testing, 12 of whom had dementia. After 10 years, 104 people were available for testing, 31 of whom had dementia. Dr Elena Moro, author of the study, said: “These results are very encouraging for people with Parkinson’s and their families that they can take advantage of the benefits of deep brain stimulation without worrying about it increasing the likelihood of developing dementia.”
Researchers “stunned” by study that raises hopes for Parkinson’s treatment
A new study reprogramming cells to replace reduced dopamine neurons in the brain could be used to reverse symptoms of Parkinson’s and other neurological conditions. As part of the study – conducted by the University of California San Diego (UCSD) – researchers found a way to convert star-shaped brain cells called astrocytes into cells producing dopamine. The team used the method to treat mouse models of Parkinson’s, administering the treatment into the areas of the brain that typically lose dopamine producing neurons. This restored reduced dopamine production to normal levels and reversed the symptoms of Parkinson’s. The researchers will continue to optimise the therapy in other mouse models of Parkinson’s before testing it on people with the condition. William Mobley, a neurosciences professor at UCSD, said: “I was stunned at what I saw. This whole new strategy for treating neurodegeneration gives hope that it may be possible to help even…
Could a magnetically powered implant treat Parkinson’s tremors?
A tiny surgical implant about the size of a grain of rice that can be implanted with minimally invasive surgery may be used to treat tremors in people with Parkinson’s. Developed by a team of researchers at Rice University, US, the implant uses a thin film of magnetoelectric material to convert acoustic waves from the brain’s magnetic field into electrical voltage. The device produces the same high-frequency signals as clinically approved implants used to treat Parkinson’s, epilepsy and other conditions – and eliminates the need for battery or wired power supply. In an initial study, the researchers showed that the implants worked in rodents. Professor Jacob Robinson, corresponding author of the study, said: “Our results suggest that using magnetoelectric materials for wireless power delivery is more than a novel idea. These materials are excellent candidates for clinical-grade, wireless bioelectronics.”